Perjeta® (pertuzumab) first treatment for advanced breast cancer to extend surviv

[News]

Perjeta, in combination with Herceptin® (trastuzumab) and chemotherapy (docetaxel), can extend survival in women with previously untreated, advanced HER2-positive breast cancer to over four and...

More... (http://www.medicalnewstoday.com/releases/283126.php)